While the top- and bottom-line numbers for United Community Banks (UCB) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
United Community Banks (UCB) came out with quarterly earnings of $0.57 per share, missing the Zacks Consensus Estimate of $0.60 per share. This compares to earnings of $0.45 per share a year ago.
UCB SA's solid buy case is driven by Bimzelx's impressive performance and robust financials despite a temporary 19% EBITDA decline due to product launch investments. Bimzelx, approved for psoriasis and hidradenitis suppurativa, is forecasted to become a blockbuster, potentially generating over €6 billion in peak sales. UCB maintains solid EBITDA margins and a healthy net debt-to-EBITDA ratio of 1.6x, providing financial stability and supporting future earnings growth.
United Community Banks (UCB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UCB SA (OTCPK:UCBJF) Q2 2024 Earnings Conference Call July 25, 2024 8:00 AM ET Company Participants Antje Witte - Head, IR Jean-Christophe Tellier - CEO Sandrine Dufour - CFO Emmanuel Caeymaex - CCO Iris Loew-Friedrich - CMO Conference Call Participants Xian Deng - UBS Brian Balchin - Jefferies Stacy Ku - Cowen Peter Verdult - Citi Thomas Vranken - KBC Yifeng Liu - HSBC Antje Witte Good morning, good afternoon, good evening. Welcome to the UCB Half Year 2024 Capital Market call.